Cardiff Oncology Inc (XE7C.SG)
| Previous close | 1.0550 |
| Open | 1.0850 |
| Bid | 1.0700 x 0 |
| Ask | 1.1100 x 0 |
| Day's range | 1.0400 - 1.0850 |
| 52-week range | 0.8770 - 5.5000 |
| Volume | |
| Avg. volume | 9 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024. Details of the presentations can be found below. Presenters: Mark Erl
- GlobeNewswire
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below. H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQLocation: The Nasdaq Headquarters, New York CityPresenter: Mark Erlander, CEOF
Simply Wall St.Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
Cardiff Oncology ( NASDAQ:CRDF ) First Quarter 2024 Results Key Financial Results Net loss: US$10.0m (loss narrowed by...
